Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 - PubMed (original) (raw)
Clinical Trial
. 2007 Mar 1;25(7):799-804.
doi: 10.1200/JCO.2006.08.3089. Epub 2007 Feb 5.
David M Lucas, Gordon W Dewald, Donna S Neuberg, John C Reed, Shinichi Kitada, Ian W Flinn, Martin S Tallman, Frederick R Appelbaum, Richard A Larson, Elisabeth Paietta, Diane F Jelinek, John G Gribben, John C Byrd
Affiliations
- PMID: 17283363
- DOI: 10.1200/JCO.2006.08.3089
Clinical Trial
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
Michael R Grever et al. J Clin Oncol. 2007.
Abstract
Purpose: Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome.
Patients and methods: We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients.
Results: Complete response (CR) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P = .00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL; P < .0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P = .0002) or del(11q22.3) (hazard ratio, 1.904; P = .006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgVH mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS.
Conclusion: These results support the use of interphase cytogenetic analysis, but not IgVH, CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies.
Similar articles
- Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G. Laurenti L, et al. Ann Hematol. 2008 Nov;87(11):891-8. doi: 10.1007/s00277-008-0527-3. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587576 Clinical Trial. - Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Byrd JC, et al. J Clin Oncol. 2006 Jan 20;24(3):437-43. doi: 10.1200/JCO.2005.03.1021. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344317 - p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M, Giraldo P, Agirre X, Larráyoz MJ, Rubio-Martinez A, Rubio-Felix D, Calasanz MJ, Odero MD. Valgañón M, et al. Br J Haematol. 2005 Apr;129(1):53-9. doi: 10.1111/j.1365-2141.2005.05405.x. Br J Haematol. 2005. PMID: 15801955 - Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J. Kharfan-Dabaja MA, et al. Cancer. 2008 Sep 1;113(5):897-906. doi: 10.1002/cncr.23671. Cancer. 2008. PMID: 18618518 Review. - Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Stilgenbauer S, et al. Leukemia. 2002 Jun;16(6):993-1007. doi: 10.1038/sj.leu.2402537. Leukemia. 2002. PMID: 12040431 Review.
Cited by
- Cytogenetic Subclone Burden: A New Biomarker Predicting Chronic Lymphocytic Leukemia Patients Outcome.
Aref S, Mansour M, Abdel-Aziz S, Sabry M, Aref M, El Dosoky W. Aref S, et al. Asian Pac J Cancer Prev. 2024 Jan 1;25(1):65-72. doi: 10.31557/APJCP.2024.25.1.65. Asian Pac J Cancer Prev. 2024. PMID: 38285768 Free PMC article. - Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH, Wu YY, Huang TC, Lin C, Zou YF, Cheng JC, Chen PH, Jhou HJ, Ho CL. Lee CH, et al. Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD013474. doi: 10.1002/14651858.CD013474.pub2. Cochrane Database Syst Rev. 2024. PMID: 38174814 Review. - Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
Yang J, Yang L, Tordon B, Bucher O, Nugent Z, Landego I, Bourrier N, Uminski K, Brown K, Squires M, Marshall AJ, Katyal S, Mahmud S, Decker K, Geirnaert M, Dawe DE, Gibson SB, Johnston JB, Banerji V. Yang J, et al. Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472. Curr Oncol. 2023. PMID: 37504332 Free PMC article. - Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.
Bantilan KS, Kay NE, Parikh SA, Rabe KG, Call TG, Leis JF, Ding W, Slager SL, Soumerai JD, Roeker LE, Mato A, Zelenetz AD. Bantilan KS, et al. Leuk Lymphoma. 2023 Feb;64(2):300-311. doi: 10.1080/10428194.2022.2148218. Epub 2022 Dec 12. Leuk Lymphoma. 2023. PMID: 36503412 Free PMC article. - Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Omi A, Nomura F, Tsujioka S, Fujino A, Akizuki R. Omi A, et al. J Clin Exp Hematop. 2022 Sep 28;62(3):136-146. doi: 10.3960/jslrt.22002. Epub 2022 Jul 12. J Clin Exp Hematop. 2022. PMID: 35831100 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous